IGF1R and Ewing sarcoma: [24] When responses in Ewing sarcoma patients were seen, the availability of a promising agent increased referral of patients with bone sarcomas and rare tumors to early-phase clinical trials, which led to expansions of the phase I trials and subsequent phase II trials of anti-IGF-1R therapy alone [25–27] or in combination with mTOR inhibition.